Aurgalys Team
Selected Customers
Interim Management
Quantum Genomics [ALQGC]
Corporate Finance
Management Assistance
Due Diligence
Interim Management
Investor Assistance
Onxeo [ONXEO]
Diaxonhit [ALEHT]

July 8th, 2015: Aurgalys releases an Analyst Report on Quantum Genomics [Alternext:ALQGC]

juillet 15, 2015

Paris-Evry, France, July  8th, 2015 – Aurgalys, a global provider for life sciences and healthcare companies through corporate finance, business development and interim management services, issued an analyst report on Quantum Genomics

« Quantum Genomics, developing cutting-edge drugs addressing unmet medical needs in the field of cardiovascular diseases, announced it would accelerate the clinical development of QGC101 in Congestive Heart Failure (CHF). Originally planned in 2017, the phase 2a clinical study has now been scheduled to begin in mid- 2016. […] »

You can download our note (in English) at the following link:

Comments are closed.